Project Grant R01DA063209
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$768K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $499,742 Project Grant award from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program, with an award date of April 15, 2025 and an ultimate completion date of March 31, 2027, aims to develop a novel AI framework for designing new non-addictive pain relief medications to address the opioid crisis. The primary objectives are to create a generative AI system that integrates scientific knowledge and grammar-based molecular encodings to...
This Project Grant award of $159,615 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to predict craving and relapse in opioid use disorder using neurobehavioral markers of goals and habits. The key objectives are to: Track daily changes in motivational control during inpatient heroin addiction treatment with and without fentanyl use, to understand how goal-directed control evolves with abstinence. Use the...
This Project Grant award of $399,483, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel polypharmacological therapeutics for substance use disorders (SUDs). The key objectives are to generate multivalent compounds that can simultaneously target and restore imbalances in the opioid, dopaminergic, and...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $798,828 to Dark Matter Therapeutics, Inc. to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The funded project will leverage artificial intelligence (AI) to develop an integrated drug discovery platform called M3.AI that combines target-based and phenotype-based methodologies. The goal...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,088,999 Project Grant to The Trustees of Columbia University in the City of New York, effective August 15, 2024 through May 31, 2029. The objective of this project is to develop efficient statistical estimators for analyzing data fusion of multi-study, multi-outcome clinical trials for treating opioid use disorder. The project aims to: 1) create parametric and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,188,822 Project Grant (R01DA059455) to the Icahn School of Medicine at Mount Sinai. The grant will fund a 5-year research project to molecularly and cellularly profile the habenulo-interpeduncular circuit in opioid tolerance and withdrawal. The project aims to examine gene expression and neuronal calcium dynamics in the interpeduncular nucleus during chronic...